Xconomy National

Archives

by in

Entry	Author	Date	Location
Trius Antibiotic Passes Pivotal Study Against Pfizer’s Zyvox	Luke Timmerman	12/19/11	San Diego
San Diego’s Trius Therapeutics Creates Options for the Next Generation of Antibiotics	Bruce V. Bigelow	05/25/11	San Diego
Optimer Inks Potential $47.5M-Plus Deal with Cubist to Help Sell Antibiotic	Ryan McBride	04/06/11	San Diego
Biotechies Need to Get Serious About Antibiotics, Where There is Money to Be Made	Luke Timmerman	04/04/11	National
Intellectual Ventures’ Latest Big Push: Turning Med-Tech Inventions Into Cash	Luke Timmerman	10/18/10	Seattle
Trius Ends First Day Trading at $5 a Share	Bruce V. Bigelow	08/03/10	San Diego
Trius Chops IPO Price, Offers More Shares	Bruce V. Bigelow	08/02/10	San Diego
Achaogen, Flush with $56M, Seeks to Build Lasting Company with Potent Antibiotics	Luke Timmerman	07/19/10	San Francisco
Trius IPO Plans Back on Track	Bruce V. Bigelow	07/15/10	San Diego
Cubist Maintains Growth Streak, As Investors Fear Generic Threat, Thin Pipeline	Ryan McBride	01/25/10	Boston
Cubist to Acquire Calixa Therapeutics in Deal Worth up to $402.5M	Ryan McBride	12/14/09	Boston
Good Things in Threes: Trius Therapeutics Files for IPO to Fund Phase 3 Clinical Trials, Marks San Diego’s Third IPO Filing	Bruce V. Bigelow	11/09/09	San Diego
UK’s Enigma Diagnostics to Establish U.S. Headquarters in San Diego	Bruce V. Bigelow	10/27/09	San Diego
Trius Approaches Next Stage in Drug Development, China Partnerships a Hot Topic at CalAsia, Lpath Headed to Critical Juncture, & More San Diego Life Sciences News	Bruce V. Bigelow	06/18/09	San Diego
Trius Looks to Cut a Deal, Gears Up For Final Stage of Trials with New Antibiotic	Luke Timmerman	06/12/09	San Diego
Anadys Cuts Jobs, Obesity Drug Developers Show Intriguing Results, Trius Antibiotic Passes Key Test, & More San Diego Life Sciences News	Bruce V. Bigelow	06/11/09	San Diego
Trius, Developer of Antibiotic for Deadly MRSA Bacteria, Passes Key Test	Luke Timmerman	06/08/09	San Diego
Moving Fast, Trius Therapeutics Assesses Capital Needs for Late-Stage Clinical Trials	Bruce V. Bigelow	04/07/09	San Diego
Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections	Luke Timmerman	03/30/09	Seattle
Vioguard CEO Larry Ranta Takes Germ-Zapping Keyboard Into Growing Hospital Market	Gregory T. Huang	03/26/09	Seattle
Calixa Passes Key Safety Test in Clinical Trial of New Antibiotic	Luke Timmerman	03/24/09	San Diego
Novophage Forming to Combat Antibiotic Resistance with Engineered Viruses	Ryan McBride	03/05/09	Boston
Teva Takes Aim at Cubist Pharma’s Key Antibiotic Business	Ryan McBride	02/10/09	Boston
Rib-X Raises $25M in Debt Financing, Reveals Final Results of Antibiotic Trial	Ryan McBride	01/26/09	Boston
Cepheid, Maker of Test to Spot MRSA Staph Infections, Builds Growing Presence in Washington	Luke Timmerman	12/22/08	Seattle
Targanta Faces New Challenges to Raise Cash After FDA Shoots Down the Firm’s Antibiotic	Ryan McBride	12/10/08	Boston
Rib-X Reveals “Positive” Antibiotic Data	Ryan McBride	12/08/08	Boston
Simple DNA Test Spots Deadly MRSA Bacteria; Adnavance Aims To Take It Mainstream	Luke Timmerman	11/10/08	San Diego
Isis Spinoff Ibis Biosciences, Looking at DNA of Infectious Bugs, Aims to Identify What They Are, Faster	Luke Timmerman	10/27/08	San Diego
Targanta Releases Antibiotic Data	Ryan McBride	10/22/08	Boston
Page 1 of 2	next page »